Option chain shows key data for NRX Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NRX Pharmaceuticals.

NRX Pharmaceuticals (NASDAQ:NRXPW) Stock, Option Chain

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

NRX Pharmaceuticals Inc

News

Wells Fargo CFO Says The Consumer Continues To Be Strong

Cantor Fitzgerald analyst Kristen Kluska reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Overweight and maintains $21 price target.

Price Target

Reiteration

Analyst Ratings

FOLD

Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $21 Price Target

Evercore ISI Group analyst James West downgrades Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) from Outperform to In-Line and lowers the price target from $6 to $5.

Downgrades

Evercore ISI Group Downgrades Transocean to In-Line, Lowers Price Target to $5

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $80 to $76.

PTCT

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $76

Canaccord Genuity analyst Austin Moeller maintains Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) with a Buy and maintains $6 price target.

BAER

Canaccord Genuity Maintains Buy on Bridger Aerospace Gr, Maintains $6 Price Target

Cantor Fitzgerald analyst Brett Knoblauch maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Overweight and lowers the price target from $15 to $14.

APLD

Cantor Fitzgerald Maintains Overweight on Applied Digital, Lowers Price Target to $14

Evercore ISI Group analyst James West downgrades Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) from Outperform to In-Line and lowers the price target from $64 to $41.

Evercore ISI Group Downgrades Noble Corp to In-Line, Lowers Price Target to $41

OS Therapies reiterates clinical and regulatory path in recurrent, fully respected osteosarcoma with lung metastases, an indication with no currently approved treatments.
 &nbsp;

OSTX

OS Therapies Says Phase 2b Clinical Trial Of OST-HER2 Achieves Primary Endpoint With Statistical Significance In Prevention Of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Interview

BlackRock CEO Larry Fink Says Don't Believe You'll See BlackRock In The Market Buying Whole Companies

Evercore ISI Group analyst James West downgrades Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) from Outperform to In-Line and lowers the price target from $48 to $39.

Evercore ISI Group Downgrades Helmerich & Payne to In-Line, Lowers Price Target to $39

WIIM

Bank of New York Mellon shares are trading higher following better-than-expected Q4 financial results.

SPRC

SciSparc Says It Is Granted 180-Day Extension Until July 14, 2025, By Nasdaq To Regain Compliance With Minimum Bid Requirement

GS: 3% &#x7C; <a href="https://www.benzinga.com//node/42999133">Goldman Sachs Q4 Investment Banking Fees Rose 24% YoY, Global Banking &amp; Markets Revenue Rose 33%, Provision For Credit Losses Fell 39%</a>
&nbsp;
VCEL: -12% &#x7C; <a href="https://www.benzinga.com//node/42997435">Vericel shares are trading lower after the company issued preliminary FY24 and Q4 net revenue below estimates.</a>
&nbsp;
COMP: 11% &#x7C; <a href="https://www.benzinga.com//node/42998131">Compass shares are trading higher after the company raised its Q4 and FY24 guidance.</a>

Movers

Trading Ideas

COMP

VCEL

Market-Moving News for January 15th

AVXL

Anavex Life Sciences Reveals Peer-reviewed Publication Of Oral Blarcamesine Phase IIb/III Data In Journal Of Prevention Of Alzheimer's Disease

Seaport Global analyst Kenneth Zener upgrades KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) from Sell to Neutral.

Upgrades

Seaport Global Upgrades KB Home to Neutral

Prairie expects Average Daily Production: 7,000 – 8,000 barrels of oil equivalent per day (BOEPD), representing a ~300% increase year-over-year.
Prairie plans to actively pursue additional strategic acquisition opportunities, the completion of which will result in an update to guidance to reflect the enhanced scale and value of the Company.

Guidance

PROP

Prairie Operating Expects 2025 Net Income  Of $69M - $102M, Adjusted EBITDA Of $100M - $140M,

Earnings

Goldman Sachs Total Loans Increased 7% During The Year

QBTS

D-wave Quantum Inks Pact With Carahsoft Partner To Expand Distribution Of Quantum Computing Solutions To The Public Sector

Rosenblatt analyst Blair Abernethy maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and maintains $18 price target.

SVCO

Rosenblatt Maintains Buy on Silvaco Group, Maintains $18 Price Target

ZLAB

Zai Lab Highlights Topline Results For TIVDAK In China Subpopulation Of Global Phase 3 innovaTV 301 Trial In Patients With Recurrent or Metastatic Cervical Cancer

NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

NRXP

NRXPW

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

NRX Pharmaceuticals

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

NRX Pharmaceuticals

NRX Pharmaceuticals (NRXPW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga